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Abstract
The E6 oncoprotein from high-risk genus alpha human papillomaviruses (a-HPVs), such as HPV 16, has been well
characterized with respect to the host-cell proteins it interacts with and corresponding signaling pathways that are
disrupted due to these interactions. Less is known regarding the interacting partners of E6 from the genus beta
papillomaviruses (b-HPVs); however, it is generally thought that b-HPV E6 proteins do not interact with many of the proteins
known to bind to a-HPV E6. Here we identify p300 as a protein that interacts directly with E6 from both a- and b-HPV types.
Importantly, this association appears much stronger with b-HPV types 5 and 8-E6 than with a-HPV type 16-E6 or b-HPV type
38-E6. We demonstrate that the enhanced association between 5/8-E6 and p300 leads to p300 degradation in a
proteasomal-dependent but E6AP-independent manner. Rather, 5/8-E6 inhibit the association of AKT with p300, an event
necessary to ensure p300 stability within the cell. Finally, we demonstrate that the decreased p300 protein levels
concomitantly affect downstream signaling events, such as the expression of differentiation markers K1, K10 and Involucrin.
Together, these results demonstrate a unique way in which b-HPV E6 proteins are able to affect host-cell signaling in a
manner distinct from that of the a-HPVs.
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Introduction
Human papillomaviruses (HPVs) are a large family of DNA
tumor viruses that infect both cutaneous and mucosal epithelium,
and lead to a range of pathologies, from benign papillomas to
cancerous lesions. Over 130 different HPV types have been
identified and divided into a number of genera based on DNA
sequence homologies [1]. The best-studied HPVs are those of the
alpha genus (a-HPVs), and include both low-risk (HPV types 6
and 11) and high-risk (HPV types 16 and 18) viruses. Low-risk
HPVs have been most often associated with genital warts and non-
cancerous papillomas, whereas the high-risk HPVs have been
shown to be the etiologic agent in cervical cancer, as well as other
anogenital carcinomas and a subset of head and neck cancers
[2,3]. Recently, another group of HPVs, the beta-HPVs (b-HPVs)
have become the subject of interest due to their possible
involvement in squamous cell skin carcinoma (SCSC) [4,5,6,7].
All HPVs encode the E6 and E7 oncoproteins, which are
responsible for numerous physiological changes within the infected
host cell [reviewed in 8,9]. However, E6 and E7 proteins differ
functionally among different HPV genera, species and types. In
the a-HPV genus, some E6 functions are conserved between both
high- and low-risk HPV types, including association with the E3
ubiquitin ligase E6AP [10,11,12,13] and degradation of the pro-
apoptotic protein Bak [14,15]. Conversely, many E6 functions are
manifested primarily by high-risk a-HPVs, including the activation
of telomerase [16,17,18] and the degradation of a number of
proteins including p53 [19] and PDZ domain containing proteins
such as hDlg [20,21], hScrib [22], MAGI [23,24], MUPP1 [25],
and PTPN3 [26,27]. Not surprisingly, some of these functional
differences can be attributed to variations in the E6 amino-acid
sequence [24,28]. For example, only high-risk a-HPVs harbor a
PDZ domain, which explains why they are able to associate with
PDZ proteins and low-risk E6 proteins are not.
While the functions of E6 from both the high- and low-risk a-
HPVs have been well studied, little is known about how E6 from
b-HPVs contribute to viral pathogenicity. Recent studies have
demonstrated that like a-HPV E6, some b-HPV E6 proteins are
capable of activating telomerase, and interacting with Bak and
E6AP [29,30], however other well-documented E6 functions are
not conserved between these two genera. For example, as b-HPV
E6 proteins (like the low-risk a-HPV E6 proteins) lack a PDZ
domain, they are unable to interact with and disrupt key polarity
signaling pathways, as do high-risk a-HPV E6 proteins. Moreover,
while some b-HPV E6 proteins, like 38E6, have been shown to
perturb p53 signaling through transcriptional activation of
deltaNp73 [31,32], most b-HPV E6 proteins are unable to bind
p53, making it unclear as to whether they are capable of
inactivating p53 signaling; a crucial step in carcinogenesis for
the high-risk a-HPVs. It is unclear what other protein interactions
occur between the b-HPV E6 proteins and host-cell proteins, the
subsequent signaling pathways that may be disrupted due to these
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development of SCSC.
One protein that has garnered interest due to its ability to
interact with E6 from both a- and b-HPVs, Bovine Papillomavirus
(BPV), and Cottontail Rabbit Papillomavirus (CRPV) is the
histone acetyltransferase p300 [33,34,35,36,37,38]. p300 is a
central hub in numerous signaling pathways, and consequently has
been shown to associate with over 100 different proteins
[Reviewed in 39,40], thus the potential for E6 to disrupt important
signaling pathways via association with p300 is vast. E6 from high-
risk a-HPVs has been shown to bind to three distinct regions of
p300; the C/H1 domain, the C/H3 domain and the C-terminus,
and disrupt important p300-dependent signaling events such as
p53 and NFKB transactivation [34,36,38]. Conversely, association
of E6 from low-risk a-HPVs appears to be confined to the C/H1
region, and conflicting evidence has been reported as to whether
or not this association alters p300-mediated signaling [34,36,38].
Interestingly, as seen with E6 from the high-risk a-HPVs, BPV
1E6 and b-HPV 8E6 have both been shown to bind to the C/H3
region of p300, while 8E6 is also capable of binding to the C/H1
and C-terminal domains [33,35]. This association has been shown
to attenuate p53 transactivation in the case of BPV 1E6 [35],
however it is unknown if 8E6 causes the same effect. Most
recently, CRPV E6 and b-HPV 38E6 were both shown to interact
with full-length p300, and these interactions also attenuated p53
signaling [37]. As can be seen, E6 proteins from different HPVs
associate with different domains of p300 with different effects.
Likewise, at least two distinct regions of E6 have been implicated
in this interaction; the region encompassing the second zinc-finger
domain corresponding to aa 100-147 of 16E6 [33,34,38], and a
more N-terminal region corresponding to aa 75–84 of 38E6 [37].
The region of 8E6 that bound p300 was mapped to residues 132–
136 [33]. Thus, even when associating with the same protein, E6
from different HPVs handle this interaction in a unique manner.
In order to better understand what signaling pathways may be
altered by b-HPV E6, we set out to identify host-cell proteins that
might interact with b-HPV E6 proteins. GST-pulldowns were
performed using recombinant GST-E6 proteins from a number of
b-HPVs and lysates from human foreskin keratinocytes (HFKs)
The isolated complexes were then analyzed by mass spectrometry.
Here we describe p300, as a protein that interacts with all of the
E6 proteins tested, but with different strengths and in turn
different consequences. Importantly, we found that b-HPV 5 and
8E6 bound to p300 very strongly, which in turn led to the
proteasomal mediated degradation of the p300 protein. We
provide evidence that degradation is mediated by E6 occluding the
AKT-phosphorylation site on p300, which, when phosphorylated,
maintains the stability of p300 within the cell. Finally, we
demonstrate that lower p300 levels in HPV 5 and 8E6 expressing
cells, in turn, affects normal p300-dependent signaling pathways.
Results
The E6 proteins from HPV types 5, 8, 38 and 16 associate
with p300
In order to identify the cellular interacting partners of various b-
HPV E6 proteins, N-terminally GST-tagged E6 proteins from b-
HPV types 5, 8, and 38 and a-HPV type 16 (as a control) were
purified and incubated with whole cell lysates from primary
human foreskin keratinocytes (HFKs). Interacting proteins were
extracted using glutathione beads, and identified by mass
spectrometry following SDS-PAGE separation. This resulted in
the identification of hundreds of potential E6 interacting proteins,
including those that interacted with all of the purified E6 proteins
tested, and those that interacted with only select E6 proteins (see
Table S1). Importantly, we were able to identify E6AP, hScrib,
and hDlg peptides with purified 16E6, thus validating the efficacy
of our pulldown and identification protocol.
Of particular interest, 9–12 unique peptides corresponding to
the histone acetyltransferase p300 were identified in the lysates
incubated with either HPV5 or 8E6. Four peptides from the
related protein, CBP, were also identified from lysates incubated
with 8E6. Surprisingly, no p300 or CBP peptides were identified
from lysates incubated with HPV 16 or 38E6, even though an
association with p300 has previously been shown with E6 from
these HPV types [34,36,37,38]. To verify the interaction with
p300, lysates from parallel GST-pulldown assays were subjected to
immunoblot analysis, in which membranes were probed using an
antibody for p300. Interestingly, p300 co-immunoprecipitated
with each of the b-HPV types tested, as well as with a-HPV type
16E6 (Figure 1A). However, the interaction between p300 and E6
from b-HPV types 5 and 8 was much stronger than that between
b-HPV 38E6 or a-HPV 16E6, as evidenced by the relative signal
intensities on the immunoblot. Importantly, differences in the
magnitude of the interaction of E6 and p300 among different types
has not been previously reported and suggests that some E6
proteins may interact with p300 in a unique manner to affect p300
functions.
To verify the interaction between p300 and E6 in vivo,C -
terminally HA-tagged E6 proteins were expressed in HFKs, and
E6 expression verified by immunoblot (Figure 1B ‘‘In’’ lanes). We
were unable to express 16E6-HA at sufficiently high levels needed
for comparative binding assessment, therefore only 5-, 8- and
38E6-HA are shown in Figure 1B and C. E6-HA expressing cell
lysates were then incubated with an anti-HA antibody to
immunoprecipitate complexes that bound to E6. Subsequent
immunoblotting demonstrated that 5, 8 and 38 E6 all interacted
with p300 in vivo, and verified that the interaction of 5 and 8E6
with p300 was many times stronger than that seen with 38E6
(Figure 1B). Co-immunoprecipitations were repeated in the
reverse direction, by pulling down with an anti-p300 antibody,
followed by immunoblot analysis against HA. Once again, p300-
E6 interactions were seen in 5, 8 and 38E6-HA expressing cells,
with 5, and 8 E6 interactions being the highest (Figure 1C). Taken
Author Summary
Human papillomaviruses (HPVs) are a family of more than
100 different viruses that cause a wide range of
pathologies, from benign warts to cervical cancer. One
subgroup of HPVs, the beta-HPVs, have recently become a
topic of interest due to their potential involvement in
squamous cell skin cancer. However, unlike the HPVs
involved in cervical cancer, little is known with regards to
how the beta-HPVs may facilitate cellular changes that
would allow cancerous lesions to develop. Here we have
identified a host-cell protein, p300, which interacts
strongly with the E6 oncoprotein from two beta-HPVs,
HPV 5 and HPV 8. We show that this interaction
subsequently blocks another cellular protein, AKT, from
binding to and stabilizing p300. By blocking this associ-
ation, p300 is targeted for degradation, and thus is present
in lower amounts than in normal cells. Importantly,
because p300 is involved in numerous cell processes such
as DNA repair, cell growth, and differentiation, the
potential for E6 disrupting a number of cellular signaling
pathways is vast. Taken together, our findings shed new
light on how the beta-HPVs may facilitate carcinogenesis.
HPV 5 and 8E6 Induce p300 Degradation
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protein from multiple b-HPV types. Moreover, the observed
differences in the magnitude of this interaction suggests there may
be different consequences to p300-mediated signaling events in
cells expressing each of these E6 proteins.
b-HPV 5 and 8E6 degrade p300 in a proteasomal-
dependent, but E6AP-independent manner
Given the observation that 5 and 8E6 interacted with p300 to
such a great extent, we wished to determine the consequences of
this interaction in E6 expressing cells. Importantly, the interaction
of 16E6 with p300 has previously been shown to alter a number of
signaling pathways, including p53 activation [34,36,38]. More-
over, while 8E6 has previously been shown to interact with p300,
the consequences of this interaction with respect to host-cell
signaling has not been examined [33]. We first wished to
determine if E6 expression had an effect on p300 protein levels
within the cell, as the stability of many proteins known to interact
with high-risk E6 is altered. Cell lysates from vector control
LXSN, or E6-expressing HFKs were analyzed by immunoblotting
for p300. Surprisingly, levels of p300 protein were decreased in
cells expressing 5 and 8E6 as compared to cells expressing either
38E6, 16E6 or vector alone (Figure 2A). Importantly, expression of
a p300-binding deficient 8E6 mutant harboring a 5aa deletion
between residues 132–136 (designated here as D8E6, [33], see
Table S2 for E6 alignment at these residues) did not lead to
decreased levels of p300, indicating that association between the
two proteins is necessary for this response. Real-time RT-PCR
demonstrated that levels of p300 mRNA remain unchanged in
each of these cells (Figure 2B), suggesting that the lower levels of
p300 seen in 5 and 8E6 expressing cells may be due to degradation
of the p300 protein. To ensure that 5E6 or 8E6 expression was
required for p300 degradation, siRNAs for each respective E6
protein were transfected into LXSN, 5E6 or 8E6 expressing cells,
and lysates harvested for RNA and protein. E6 mRNA
knockdown was verified by real-time RT-PCR for the respective
E6 (Figure 2C). Examination of p300 protein levels in these cells
revealed that p300 protein levels increased upon E6 knockdown
for both siRNAs targeting 5E6 and one siRNA targeting 8E6
(Figure 2D). The second 8E6-specific siRNA did not lead to
increased p300 expression, but was also the siRNA with the least
efficient knockdown of E6, indicating a possible dose-response
effect of E6 expression toward p300 degradation (Figure 2C).
High-risk E6 proteins such as 16E6 are well known for their
ability to promote protein degradation in a proteasomal-
dependent manner. To test if the decreased levels of p300 protein
observed in 5 and 8E6 expressing cells was due to proteasomal
degradation, proteasomal inhibitors MG132 and Lactacystin were
used. LXSN control and E6 expressing cells were incubated with
either MG132 or Lactacystin for 2 hrs prior to cell lysis. Cell
lysates were then harvested and analyzed by immunoblot to
determine the levels of p300 protein (Figure 3A and 3B). As a
control, p53 levels were also analyzed, as p53 is known to be
degraded by 16E6 in a proteasomal-mediated fashion [19]. In the
absence of inhibitor, p53 was degraded in 16E6 expressing cells;
however, in the presence of either MG132 or Lactacystin, p53
levels rebounded. Similarly, in cells expressing 5 or 8E6, p300
levels were much lower than in control cells in the absence if
inhibitor; however upon pre-incubation with either MG132 or
lactacystin p300 levels increased. Thus, the lower levels of p300
protein seen in 5 and 8E6 expressing cells is mediated by the
proteasome. The proteasome inhibitors also caused a slight
increase in p300 levels in the LXSN, 38E6 and 16E6 expressing
cells, suggesting a general mechanism for regulating p300 stability.
It should be noted that although we have demonstrated that the
proteasome is involved in the modulation of p300 levels, we can
not rule out the possibility that this is occurring through the
proteasomal degradation of another factor involved in p300
translation, rather than via direct degradation of p300 itself.
16E6 is known to mediate the proteasomal degradation of many
proteins through an interaction with the E3 ubiquitin ligase E6AP
[11]. Importantly, E6AP has been shown to interact weakly with
many of the b-HPV E6 proteins [30]. We therefore wished to
determine if E6AP was involved in HPV 5 and 8E6 mediated
degradation of p300. LXSN control and E6 expressing cells were
transfected with pools of 4 individual siRNAs directed against
E6AP or non-targeting controls. Cells were harvested 72 hr post-
transfection and assayed by immunoblot for E6AP, p53, and p300
(Figure 3C). Importantly, in all cells transfected with the pooled
siRNAs targeting E6AP, E6AP protein levels were drastically
reduced. This was confirmed at the mRNA level using real-time
RT-PCR (data not shown). Very low basal levels of E6AP were
present in 16E6 cells, consistent with previous observations that
Figure 1. E6 from a and b HPVs bind p300 with different strengths. (A) Representative immunoblot showing the levels of p300 co-
precipitating with various GST-tagged E6 proteins. Equal levels of input GST-E6 are demonstrated by the GST immunoblot in the lower portion of the
figure. (B) HFKs expressing E6-HA were immunoprecipitated with a HA antibody (HA) or mouse Immunoglobulin G (IgG) as a negative control and
immunoblotted with a p300 and HA antibody. (C) Identical cell lysates were immunoprecipitated with a p300 antibody (p300) or IgG control and
immunoblotted with a p300 and HA antibody. Input is equal to 5% of total protein lysate.
doi:10.1371/journal.ppat.1002211.g001
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PLoS Pathogens | www.plospathogens.org 3 August 2011 | Volume 7 | Issue 8 | e1002211Figure 2. b HPV 5 and 8E6 binding to p300 leads to p300 degradation. (A) Representative immunoblot showing the levels of p300 in LXSN
and E6-expressing HFKs. Actin is shown as a loading control. (B) p300 mRNA levels in LXSN and E6-expressing HFKs. Relative levels of p300 mRNA
were calculated using the DDCT method with GAPDH to normalize mRNA levels within each sample. Values shown are the mean fold-change in each
sample compared to the LXSN vector control. Error bars represent the standard deviation for each sample (n=3). (C) 5E6 and 8E6 mRNA levels
following transfection of E6 siRNA. Relative levels of 5 and 8E6 mRNA were calculated using the DDCT method with GAPDH to normalize mRNA levels
within each sample. Values shown are the mean fold-change in each sample for one representative experiment. (D) Representative immunoblot
showing the levels of p300 in LXSN, 5E6 and 8E6 expressing cells following transfection with siRNAs specific for each E6. Actin is shown as a loading
control. siRNA #1* and #2* in LXSN cells represent a 50/50 mixture of 5E6 siRNA #1 and 8E6 siRNA #1, and 5E6 siRNA #2 and 8E6 siRNA #2
respectively.
doi:10.1371/journal.ppat.1002211.g002
Figure 3. b HPV 5 and 8E6 degrade p300 in a proteasomal-dependent, E6AP-independent manner. (A) LXSN and E6-expressing HFKs
were treated with DMSO (2) or MG132 (+) 2 hr prior to harvesting cell lysates. Lysates were then analyzed by immunoblot for p300, p53 and
nucleolin (control). (B) LXSN and E6-expressing HFKs were treated with DMS0 (2) or Lactacystin (+) 2 hr prior to harvesting cell lysates. Lysates were
then analyzed by immunoblot for p300, p53 and nucleolin. (C) E6AP was knocked down by transfection of LXSN or E6-expressing HFKs with a pool of
4 siRNAs targeting E6AP (+) and compared to cells mock treated by transfection with a pool of 4 non-targeting siRNAs (2). 72 hr post transfection,
lysates were harvested and analyzed by immunoblot for p300, E6AP, p53 and nucleolin (control). (D) E6AP was knocked down using 2 individual
siRNAs from the above pool (1 and 2) and compared to cells mock treated with 1 individual non-targeting siRNA (2). 72 hr post transfection, lysates
were harvested and analyzed by immunoblot for p300, E6AP, p53 and nucleolin (control).
doi:10.1371/journal.ppat.1002211.g003
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[41].
As above, p53 was used as a control, as it is known to be
degraded in an E6AP-dependent manner. In 16E6 cells transfect-
ed with the pooled control siRNA, p53 levels were decreased as
compared to LXSN control cells. Conversely, when these cells
were transfected with a pool of siRNAs targeting E6AP, p53 levels
increased. Surprisingly, the E6AP targeting siRNA pool had no
effect on the levels of p300 in either 5 or 8E6 expressing cells. p300
levels were lower than control cells in the presence of the control
siRNA pool, and remained unchanged upon transfection with the
E6AP targeting pool, indicating that p300 degradation was E6AP
independent in these cells. To verify these results and minimize
any potential off target effects from a pool of 4 siRNAs we
repeated these experiments using 2 of the 4 siRNAs from the pool
individually. Similar to the results seen with the pooled siRNAs,
each individual siRNA was able to knockdown the majority of
E6AP in the cell (Figure 3D). Likewise, the effects on p53 and p300
were similar to that seen above. In 16E6 expressing cells p53
protein levels rebounded in cells transfected with either targeting
siRNA, while the siRNAs had no effect respect to p300 levels in
either 5 or 8E6 expressing cells. Taken together these data
demonstrate that while p300 degradation is indeed dependent on
the proteasome, it is independent of the E3 ubiquitin ligase E6AP.
p300 degradation is modulated by AKT activity
As p300 degradation was shown to be proteasome-dependent,
but E6AP-independent, we wished to determine the mechanism
by which E6 may affect degradation. Importantly, p300 stability
has previously been shown to be modulated by AKT activation
[42]. A consensus AKT phosphorylation site is located within the
p300 C-terminus, between amino acids 1829–1834, near the CH3
and Q regions of the protein [43,44] (Figure 4A). Phosphorylation
of the S1834 within this site has been shown to be required for
stabilization of the p300 protein; if this site is mutated or AKT
signaling inhibited, then p300 protein is targeted for degradation
in a proteasomal-dependent manner. In support of a role for AKT
in b-HPV 5 and 8E6 mediated p300 degradation, we found that
p300 levels were not lowered in 5- and 8E6 expressing HT1080
cells, which harbor constitutively active AKT [45] (Figure 4B).
Importantly, p300 protein levels in these samples were analyzed
with an antibody specific only to p300, and not cross-reactive to its
related protein, CBP. In contrast, an antibody specific to CBP
showed equal CBP protein levels in all samples from both HFK
and HT1080. Additionally, there were no differences in AKT or
pAKT levels between LXSN control or any of the E6 expressing
cells within their respective cell lines (Figure 4C), indicating that
E6 expression itself was not perturbing cell-wide AKT activation.
Thus, while AKT activation appears to be involved in 5 and 8E6
mediated degradation of p300, AKT activation itself is not altered
by E6 expression.
To further demonstrate the importance of AKT in E6 mediated
p300 degradation, we employed the use of an activator of AKT
signaling, Ro 31-8220 [46], and an inhibitor of AKT signaling,
Ly294002 [47]. We hypothesized that activating AKT with Ro 31-
8220 would increase p300 levels in 5 and 8E6 expressing cells, as
the protein would no longer be targeted for proteasomal
degradation. Conversely, inhibiting AKT with Ly294002 would
destabilize p300 across all of the cell lines, and total p300 protein
levels would be lower than their corresponding non-drug treated
controls. Indeed, when cells were pre-treated with Ro 31-8220 to
activate AKT, p300 levels were increased in all cells, but most
dramatically in 5 and 8E6 expressing cells, which initially
harbored the least amount of p300 to begin with (Figure 4D).
Conversely, when cells were pre-treated with Ly294002 to inhibit
AKT, p300 levels were depleted in both LXSN control, and E6
expressing cells (Figure 4E). The observation that p300 protein
levels also change in non-E6 expressing cells is expected as this is a
normal mechanism of p300 regulation in the absence of E6. Also
of note, the levels of pAKT in the lysates from 5 and 8E6
expressing cells used in Figure 4D and E suggest that 5 and 8E6
may be activating AKT, differing from the data shown in
Figure 4C where no such difference was seen. Over most
experiments we consistently saw no differences in AKT activation,
as stated above.
Finally, utilizing a pCMV-HA-p300 expression vector, we
generated two mutants of p300 at the AKT phosphorylation site,
S1834. These mutants included S1834A, which should not be able to
be phosphorylated by AKT and thus shouldn’t be affected by E6
expression; and S1834E, in which the serine is replaced by glutamic
acid, and thus represents a phospho-mimic which should also not be
affected by E6 expression, and additionally should stabilize the
protein leading to higher levels when assessed by immunoblotting.
Both of these mutants have been previously described and tested with
respect to AKT mediated effects on p300[43]. LXSN, 8E6 and D8E6
expressing HFKs were transiently transfected with either WT-
HAp300, HAp300-S1834A, or HAp300-S1834E. 48 hours post-
transfection, samples were harvested and assessed by western blot
with an antibody to HA, endogenous p300, and Actin as a loading
control (Figure 4F). WT-HAp300 mimicked the endogenous p300 in
that both proteins were present in lower levels in 8E6, but not D8E6
expressing cells, when compared to LXSN. HAp300-S1834A and
HAp300-S1834E both showed minimal decrease in their respective
protein levels in 8E6 expressing cells, as compared to LXSN or D8E6
expressing cells, indicating that mutation at this site significantly
abrogates 8E6-mediated degradation of p300. Moreover, total levels
of HAp300-S1834E were much higher in all three cell lines than that
of WT or the S1834A mutant p300, indicating that this protein has
been stabilized due to the glutamic acid acting as a phospho-mimic at
this site. Finally, all cell lines were re-probed with a p300 antibody to
gauge the levels of endogenous p300 protein within each sample. In
all cases, regardless of which p300 expression vector was used for
transient transfection, endogenous p300 levels were lower in the 8E6
cell lysates as compared to LXSN or D8E6 expressing lysates. Taken
together, these data further confirm that 5 and 8E6 mediated p300
degradation involves AKT signaling.
E6 competes with AKT for binding to p300
The AKT phosphorylation site in the p300 C-terminus lies
within a well-defined region of p300 that has been shown to be the
binding site of numerous other p300-interacting proteins,
including E6. 8E6 interaction with p300 at this region has been
finely mapped, and has been shown to bind to the region
encompassing aa 1770–1814 [33], which is directly adjacent to the
AKT phosphorylation site at aa 1829–1834. We hypothesized that
due to the proximity of the AKT and E6 binding sites on p300,
strong binding of 8E6 would in turn prevent AKT from binding,
phosphorylating and in turn stabilizing p300, thus leading to p300
degradation. To test this hypothesis a competitive binding assay
was performed using purified GST-tagged 8E6, FLAG-tagged
p300 and His-tagged AKT. Beginning with equimolar amounts of
p300 and AKT, increasing molar amounts of 8E6 were
introduced. The complexes were then pulled down using anti-
FLAG agarose beads, and eluted samples subjected to SDS-PAGE
and immunoblot analysis for each of the proteins (Figure 5A and
B). As can be seen, as greater amounts of E6 was added, more E6
was pulled down with p300, and correspondingly less AKT was
recovered. The experiment was then repeated by starting with
HPV 5 and 8E6 Induce p300 Degradation
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increasing molar amounts of AKT. Once again, complexes were
pulled out using anti-FLAG agarose beads and analyzed as above
(Figure 5C and D). Similarly, as greater amounts of AKT were
added, more AKT was found to be associated with p300, and
correspondingly less E6 was recovered. Taken together, these
results demonstrate that E6 and AKT compete for binding to
p300, and imply that this competition could preclude AKT from
phosphorylating the activation site within the p300 C-terminus,
thus leading to de-stabilization of p300 protein levels.
5 and 8E6-mediated p300 degradation modulates the
levels of multiple markers of keratinocyte differentiation
Reduced levels of p300 protein in 5 and 8E6-expressing cells has
the potential to affect a multitude of signaling pathways. One such
pathway that has recently been shown to be specifically abrogated
by p300 knockdown is keratinocyte differentiation [48]. Introduc-
tion of shRNAs targeting p300 has been shown to attenuate both
an early differentiation marker, K1 and a late differentiation
marker, filaggrin, in both calcium-induced and raft-culture model
systems of keratinocyte differentiation [48]. Additionally, the
expression of another differentiation marker, involucrin, has
previously been demonstrated to be regulated by p300 at the
transcriptional level [49,50]. We examined the protein levels of
three differentiation markers; K10, K1 and involucrin in both
untreated, and calcium-differentiated cells harboring either 8E6,
D8E6, 38E6 or LXSN vector (Figure 6A). As expected, as calcium-
induced differentiation was allowed to proceed (see Figure S1 for
AKT/pAKT levels during differentiation, and Figure S2 for cell
morphology during differentiation), the levels of K1, K10 and
involucrin all increased substantially in LXSN control cells.
Importantly however, while a slight increase of each protein was
Figure 4. p300 degradation is modulated by AKT activity. (A) Domain structure of p300 demonstrating the location of the AKT
phosphorylation site with respect to the C/H3 and Q domains [modified from 44]. Arrows indicate the start and end of the C/EBPb binding region that
is also the binding site of many other proteins including E6 (B) Representative immunoblot showing levels of p300, CBP and nucleolin (control) in
LXSN or E6-expressing HT1080s and HFKs. (C) Representative immunoblot showing levels of p300, pAKT, total AKT and Nucleolin in LXSN and E6-
expressing cells. (D) LXSN and E6-expressing HFKs were treated with DMS0 (2) or Ro-31(+) 2 hr prior to harvesting cell lysates. Lysates were then
analyzed by immunoblot for p300, phospho-AKT, AKT and nucleolin. (E) LXSN and E6-expressing HFKs were treated with DMS0 (2) or LY294002 (+)
24 hr prior to harvesting cell lysates. Lysates were then analyzed by immunoblot for p300, phospho-AKT, AKT and nucleolin. (F) Representative
immunoblot showing levels of transiently transfected HA-p300, endogenous p300 and Actin as a loading control in LXSN, 8E6 and D8E6 cells
transfected with WT-HAp300 or p300 S1834A/E mutants.
doi:10.1371/journal.ppat.1002211.g004
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tiation, the levels of K1, K10 and involucrin in 8E6 cells relative to
that in control LXSN cells was dramatically lower; not only in
untreated cultures, but also during each timepoint during
differentiation. Strikingly, this abrogation of differentiation was
not seen in 38E6 expressing cells, indicating that this effect is not
simply a general response to HPV-E6 expression. Moreover, the
attenuated expression of differentiation markers was also not seen
in D8E6-expressing cells, indicating that p300 binding and/or
degradation are necessary to achieve this effect. To determine if
attenuation of differentiation marker expression was at the level of
transcription or translation, we examined the same cultures for
mRNA expression using real-time RT-PCR (Figure 6B). As seen
with the levels of protein expression, the levels of K1, K10 and
involucrin mRNA all increased in LXSN control cells following
the induction of calcium-mediated differentiation. Likewise, while
a slight increase in the expression of all three genes was discernable
in 8E6 expressing cells, the relative levels of each gene was
drastically reduced by 8E6 expression when compared to the
corresponding LXSN control sample. Finally, as seen with the
protein levels, both this attenuation of expression was almost
completely absent in both 38E6 and D8E6-expressing HFKs.
Thus, 8E6 expression attenuates the mRNA levels of three
different markers of differentiation; K1, K10 and involucrin.
As p300 has been shown to associate with the involucrin
promoter and enhance its transcription [49,50], we hypothesized
that p300 occupancy at the involucrin promoter would be
attenuated in 8E6 expressing cells, as these cells harbor
significantly less p300 protein. We performed ChIP analysis using
antibodies to p300 and primers to amplify the region of the
involucrin promoter known to be bound by p300 (Figure 6C).
Using occupancy at the RPL30 promoter (control provided in the
ChIP kit), and binding of IgG as controls, we verified that p300 is
approximately 6-fold enriched at the involucrin promoter in
LXSN cells, and over 10-fold enriched at the involucrin promoter
in 38E6 cells. Conversely, p300 was almost completely absent
from the involucrin promoter in 8E6 cells.
While p300 has been shown to play a role in the transcriptional
regulation of involucrin [49,50], a direct role for the involvement
of p300 in the transcriptional regulation of K1 and K10 has not
been described. Therefore, to more thoroughly demonstrate that
p300 degradation by itself is directly responsible for the altered
expression of each of the differentiation marker examined in
Figure 6, we employed the use of siRNA pools and two individual
siRNAs to knockdown p300 in non-E6 expressing cells, and
subsequently examine both the mRNA and protein from the
resulting cell lysates. In undifferentiated cell lysates, knockdown of
p300 by either an siRNA pool or two individual siRNAs resulted
Figure 5. E6 and AKT compete for binding to p300. (A) Representative immunoblot showing the levels of AKT and E6 associated with p300
under increasing molar input of E6. Input protein levels are shown at the left and represent 5% of input protein. (B) Quantitation of E6 and AKT levels
from A. 20X molar GST is shown as a control. (C) Representative immunoblot showing the levels of AKT and E6 associated with p300 under increasing
molar input of AKT. Input protein levels are shown at the left and represent 5% of input protein. (D) Quantitation of E6 and AKT levels from C.
doi:10.1371/journal.ppat.1002211.g005
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(Figure 7A). When extended to a calcium-differentiation model,
this trend was maintained following 24hr treatment with calcium-
media; while the mRNA (Figure 7B) and protein (Figure 7C) levels
for each gene increased dramatically during calcium treatment in
control cells, levels of K1, K10 or involucrin mRNA and protein
either stayed the same or increased only slightly in cells transfected
with p300 siRNA. The inability to see dramatically lower levels of
K1, K10 or involucrin mRNA or protein in undifferentiated cells
upon knockdown of p300 (Figure 7B and C) could be due to an
inability to detect a difference in samples treated with siRNA for
only 48 hrs (as opposed to the 72 hrs used for Figure 7A), or may
be due to a dose-effect from the level of p300 knockdown itself in
this particular experiment. Under more standard siRNA condi-
tions however (as used for Figure 7A), decreased mRNA
expression of each gene is consistently reproducible. Additionally,
the effect of p300 siRNA on IVL protein expression in Figure 7C
is not as dramatic as that seen with 8E6 expression in Figure 6A.
As above, this may be due to inadequate knockdown of p300 at
this particular time, or it may indicate that additional functions of
8E6 other than p300 degradation may affect IVL levels. Taken
together, these data demonstrate that 8E6-expressing cells are
attenuated in their ability to undergo calcium-mediated differen-
tiation, and this attenuation is directly mediated by the decreased
levels of p300.
Discussion
In order to identify host-cell proteins that interact with b-HPV
E6, we performed GST-pulldowns using GST-tagged E6 proteins
Figure 6. p300 degradation alters K1, K10 and IVL expression. (A) Representative immunoblot showing levels of K1, K10 and IVL protein in
LXSN, 38E6, 8E6 and D8E6-expressing HFKs during 72 hr calcium-induced differentiation. Actin levels are shown as a loading control. (B) K1, K10 and
IVL mRNA levels levels in LXSN 38E6, 8E6 and D8E6-expressing HFKs during 72 hr calcium-induced differentiation. Relative levels of each mRNA were
calculated using the DDCT method with GAPDH to normalize mRNA levels within each sample. Values shown are fold-change in each sample
compared to the LXSN (0 hr) vector control. (C) ChIP analysis using anti-p300 antibodies to pull down chromatin from LXSN control, 8E6 and 38E6-
expressing HFKs, with quantitation by real-time PCR. Values represent the enrichment of p300 at the IVL promoter shown relative to the IgG and
RPL30 negative controls. Error bars represent standard deviation (n=3, p,.01 by 2-tailed student’s T-test).
doi:10.1371/journal.ppat.1002211.g006
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analysis of the interacting complexes. We identified p300 as a
protein that interacted with all of the E6 proteins tested; albeit with
different relative strengths and different consequences to down-
stream signaling. While p300 binding to 16E6, 8E6 and most
recently 38E6, has previously been demonstrated [33,34,36,37],
the relative strengths of the two interactions had not been
examined, and the consequences of 8E6-p300 binding had not
been studied with respect to effects on host cell signaling. Here we
demonstrate not only that other b-HPV E6 proteins are also able
to interact with p300, but also show that b-HPV 5 and 8E6 bind to
p300 at relatively high levels, while b-HPV 38E6 and a-HPV
16E6 bind to the protein at much lower levels.
The importance of p300 for a myriad of signaling and
regulatory pathways has been well documented. The protein
plays a role in bridging other transcription factors to the basal
transcriptional machinery; acetylating histones to facilitate chro-
matin remodeling; regulating DNA repair, cell growth, differen-
tiation and cell death; is involved in embryogenesis; and functions
as a tumor suppressor [Reviewed in 39,40]. Not surprisingly, p300
has been shown to be mutated in a number of cancers, and
targeted by many viruses. p300 has been shown to be inactivated
by C-terminal truncation in a small percentage of cancers of
epithelial origin, including colorectal, gastric, breast, pancreatic,
cervical and ovarian, as well as in the human diffuse B-cell
lymphoma cell line RC-K8 [51,52,53,54,55,56]. Mutations in
p300 are even more common in colorectal cell lines, where 4/17
were found to harbor homozygous or heterozygous mutations
[54]. Moreover, ectopically expressing p300 in cancer lines
harboring biallelic mutations of p300 slows cell growth [57], and
p300 knockout mice have been shown to develop histiocytic
sarcomas [58]. Viral inactivation of p300 has been shown to be
mediated by oncoproteins from five different viruses; adenovirus
E1A, SV40 large T antigen, E6 and E7 from HPV, Tax protein
from HTLV-1 and A238L protein from African Swine Fever
Virus [59,60,61,62,63,64,65]. Importantly all of these oncopro-
Figure 7. p300 knockdown by siRNA is sufficient to attenuate the mRNA and protein expression of K1, K10 and involucrin. (A) p300
was knocked down using either a pool of 4 siRNAs (pool) or 2 individual siRNAs (si 1 and si 2) and compared to cells mock treated with a non-
targeting siRNA (CTR). 72 hr post transfection, lysates were harvested and analyzed for p300, K1, K10 and IVL mRNA levels. Relative levels of each
mRNA were calculated using the DDCT method with GAPDH to normalize mRNA levels within each sample. Values shown are the fold-change in each
sample compared to the siRNA control. Error bars represent standard deviation (n=2). (B) p300 was knocked down using either a pool of 4 siRNAs
(pool) or 2 individual siRNAs (si 1 and si 2) and compared to cells mock treated with a non-targeting siRNA (CTR). 48 hr post transfection, cells were
treated with either normal media or media containing 1.5 mM CaCl2 to induce differentiation. 24 hr later lysates were harvested and analyzed for K1,
K10 and IVL mRNA levels. Relative levels of each mRNA were calculated using the DDCT method with GAPDH to normalize mRNA levels within each
sample. (C) A parallel set of samples was treated as in B, and 24 hr later lysates were harvested and analyzed by immunoblot for p300, K1, K10, IVL
and Actin (control).
doi:10.1371/journal.ppat.1002211.g007
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transactivation ability of p300, which in turn mediates tumorige-
nicity. Interestingly, recent data has shown that the promoters for
p300 regulated genes vary greatly with respect to their affinities for
p300 [66], thus lowering levels of p300 (even slightly) may have
drastic consequences for the expression of genes with a relatively
low affinity site for p300, and possibly no effect on genes/
promoters with high affinity sites. Thus, even slight alterations of
this pathway by viruses or mutation can have profound effects on
cellular signaling.
Importantly, we demonstrate that the strong binding observed
between p300 and either b-HPV 5 or 8E6 does indeed have a
functional consequence for the host-cell, as the interaction inhibits
the association of AKT with its normal binding site at the p300 C-
terminus, thus targeting the p300 protein for proteasomal
degradation. We provide additional evidence that altering the
levels of E6 expression via siRNA knockdown reverses this affect in
somewhat of a dose-response dependent manner, suggesting that
differences in 5 or 8E6 expression may alter the degree of p300
degradation observed. This is important because it is still
controversial as to what the physiological levels of b-HPV E6
proteins may be in HPV infected individuals. Regardless, the
general effects of p300 knockdown in both primary and immortal
cell lines has been well studied. In primary HFKs, p300
knockdown with shRNA has been shown to delay differentiation,
allow differentiated HFKs to re-enter the cell-cycle, increase cell
proliferative capacity, extend the lifespan of cells in culture, and
regulate the acetylation and expression of p53 [48]. Additionally,
cells lacking p300 have been shown to exhibit changes
characteristic of epithelial to mesenchyme transition, including
gene expression changes, loss of cell-cell adhesion, defects in cell-
matrix adhesion and increased migration through collagen and
matrigel [67]. With respect to cell death, p300 has been shown to
regulate the sensitivity of cells to irradiation, and has a pro-
apoptotic function in the DNA damage response. Thus mutations
in tumor cells that attenuate p300 function confer resistance to
ionizing radiation and other genotoxic agents [68]. Finally, in the
context of 16E6, p300 knockdown by shRNA was shown to
induce transcription of hTERT mRNA and induce telomerase
activity [69]. Thus the discovery of p300 degradation in HPV 5
and 8 expressing cells has the potential to have far-reaching
consequences.
Indeed, our finding that the decreased p300 levels in 8E6
expressing cells leads to the attenuated expression of multiple
structural markers of differentiation has profound implications for
the HPV replicative cycle, as the ability of HPV to replicate
depends on continued cell proliferation and inhibition of terminal
differentiation. Recent studies have focused on K10 as a possible
tumor suppressor, as overexpression of this particular cytokeratin
has been shown to both inhibit cell proliferation and suppress
tumor development [70,71,72]. Thus, by inhibiting the expression
of K10 via p300 degradation, 8E6 functions to remove this
blockade. Moreover, in a transgenic mouse model, K1 and K10
expression were shown to be lost during skin tumor progression
[70]. Interestingly, loss of K1 expression and altered K10
localization have been previously demonstrated both in cultured
cells expressing the HPV 8 early region [73], and from
papillomous lesions taken from EV patients [74], however the
mechanisms by which these events occurred were not known.
Importantly, our data has now identified a link between E6
expression, p300 degradation and decreased expression of
important differentiation markers within keratinocytes.
Another important function of p300 that is of particular
relevance to HPV infection is that of regulating the activity of
p53, and as a co-factor in p53-dependent transactivation of a
number of genes. Following DNA damage, p300 acetylates p53 on
Lys 382, which stabilizes the p53/DNA complex at target
promoters [75,76,77]. Additionally, p300 can be recruited by
p53 to certain promoters, where it can act as a bridge for other
transcription factors, or act to acetylate histones [78,79].
Importantly, E6 from both high-risk and low-risk a-HPVs, as
well as BPV-1 and most recently b-HPV 38E6 have been shown to
inhibit the ability of p300 to transactivate p53 [34,35,36,37,38].
This function of E6 is independent of E6AP and does not require
p53 degradation. Rather it is thought that the interaction between
E6 and p300 may inhibit the association of p53 with p300 [34].
Thus, while only high-risk a-HPV E6 proteins are able to disrupt
p53 signaling by degrading the p53 protein itself, E6 from low-risk
a-HPVs are capable of interfering with this pathway simply
through association with p300. It is therefore tempting to speculate
that the degradation of p300 by b-HPV 5 and 8E6 represents yet
another way in which this pathway may be disrupted by the E6
oncoprotein. Preliminary evidence from our lab suggests that HPV
5, 8 and 38E6 are all capable of attenuating p300-mediated
acetylation of p53, and further studies are underway to examine
other effects these oncoproteins may have on p53 signaling.
In summary, we have identified p300 as a protein that appears
to broadly interact with the E6 oncoprotein from both alpha and
beta genera of HPV. Importantly, due to the observed differences
in the strength of this association among HPV types, different
consequences to p300 signaling occur. The relatively weak
association with 16E6 has previously been shown to allow for
inhibition of p53 signaling [34,36,38], however does not perturb
the steady state levels of p300 protein within the cell. Conversely, 5
and 8E6 bind to p300 at relatively high levels, causing the stability
of the p300 protein becomes perturbed, leading to an overall
decrease of the p300 levels within the cell. As a result, certain
proteins that depend on p300 for their regulation, like K1, K10
and IVL become de-regulated, altering their expression level, and
in turn leading to additional consequences with regard to
downstream signaling events. Importantly, given the broad role
that p300 plays in orchestrating the enhancement or repression of
transcriptional processes within the cell, the consequences of p300
degradation are likely to have far-reaching effects with regard to
HPV infection.
Materials and Methods
Reagents
Antibodies to GST(B-14), Nucleolin(C-23), E6AP(H-182),
His(H-15), EGR-1(588), p300(N-15) Actin (I-19), Cytokeratin
10/13 (DE-K13) and Involucrin (SY8) were purchased from
Santa Cruz Biotechnology; antibodies to AKT, phospho AKT
(Ser 473) and CBP were purchased from Cell Signaling
Technology; antibodies to HA (HA.11) and Keratin 1 were
purchased from Covance; antibodies to p300 (NM11) were
purchased from BD Pharmingen; antibodies to p53(DO-1) were
purchased from Calbiochem; non-cross reactive p300 antibodies
(RW128) were purchased from Millpore. siRNA pools and
individual siRNAs specific for E6AP, p300 and controls were
purchased from Dharmacon RNA Technologies. siRNA’s de-
signed to target 5E6 and 8E6 were designed and purchased from
Invitrogen (see Table S3 for sequences). Proteasome inhibitors
Lactacystin and MG132 were purchased from Calbiochem and
used at a final concentration of 20 mM. AKT inhibitor LY294002
was purchased from Cell Signaling Technology and used at a final
concentration of 10 mM. AKT activator Ro 31-8220 was
purchased from Sigma and used at a final concentration of
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AKT1 were purchased from Active Motif. EZ-view Red anti-
FLAG M2 affinity gel was purchased from Sigma.
DNA constructs and mutagenesis
All HA-tagged and untagged E6 constructs have been described
previously [29,30], with the exception of D8E6, which was
constructed by performing site-directed mutagenesis to obtain a
deletion of aa 132–136 [33] (see Table S3 for mutagenesis
primers). Expression of E6 was verified at the mRNA level
following selection (see below) by real-time RT-PCR analysis. All
primers have been previously described [29]. New primers were
designed to assess levels of D8E6 (see Table S3), as the original 8E6
primers flanked the deletion site. HA-p300-pCMV was purchased
from Upstate Biotech, and used to construct S1834A/E mutants
via site directed mutagenesis (see Table S3 for mutagenesis
primers).
Tissue culture
Primary human foreskin keratinocytes (HFKs) were derived
from neonatal human foreskins and grown in EpiLife medium
supplemented with calcium chloride (60 mM), human keratinocyte
growth supplement (Cascade Biologics, Portland, OR) and
penicillin-streptomycin. 293T cells were grown in Dulbecco’s
modified Eagle’s medium (Gibco-BRL) containing 10% fetal
bovine serum (FBS) and penicillin-streptomycin. For calcium-
induced differentiation, confluent monolayers of HFKs were
treated by withdrawal of growth factors and addition of media
containing 1.5 mM CaCl2. Stable E6-expressing cell lines were
produced using transient vesicular stomatitis virus G (VSV-G)
pseudo typed virus as previously described [29]. Briefly, E6
proteins cloned into an LXSN vector were co-transfected with
VSV-G helper plasmids into 293T cells using Fugene 6 (Roche),
and retrovirus collected at 12, 24, 36 and 48 hrs post transfection.
Transiently produced virus was concentrated by ultracentrifuga-
tion and used to infect HFK monolayers (50 to 60% confluent) in
the presence of Polybrene (8 mg/mL). Four hours after infection,
cells were washed with PBS and the media replaced. The cells
were expanded when confluent and were placed under neomycin-
G418 selection (50 mg/liter) for 7 days. HA-p300WT, HA-
p300S1834A and HA-p300S1834E were all transiently transfected
into LXSN, 8E6 and D8E6 cells using TransIT Keratinocyte
transfection reagent (Mirus), and assessed 72 hr later for levels of
both endogenous p300 and the transfected HA-p300 construct.
GST-protein purification and GST pull-down assays
Generation of N-terminally GST tagged E6 vectors was
described previously [29]. GST-E6 constructs were transformed
into BL21-AI Escherichia coli, and grown overnight at 37uCo nL B
plates containing 50 mg/ml ampicillin. Isolated colonies were used
to inoculate 20 ml LB broth containing 200 mg/ml carbenicillin
and grown overnight with shaking at 37uC. 10 ml of the overnight
culture was added to 1 L of fresh LB-carbenicillin and incubated
at 37uC with shaking for 2.5 hrs. Cultures were then transferred to
room temperature and incubated for 30 min with shaking, after
which the optical density at 600 nm of all cultures was between 0.4
and 0.6. L-Arabinose was added to each culture at a final
concentration of 0.2% to induce protein expression, followed by
growth for 4 hr at room temperature with shaking. Bacterial cells
were then harvested by centrifugation at 6,000 rpm for 15 min at
4uC, and the resulting pellets were stored at 220uC. Bacterial
pellets were resuspended in PBS-P (phosphate-buffered saline,
50 mM EDTA and protease inhibitor tablets) and lysed via two
passages through a microfluidizer, followed by a 30 min
incubation with 0.1%TritonX-100 at 4uC with end-over-end
rotation. Bacterial lysates were centrifuged at 14,000 rpm in a
JA17 rotor for 15 min at 4uC, and the pellets discarded. The
resulting supernatants were added to pre-equilibrated glutathione-
sepharose bead slurries, and incubated at 4uC for 1 hr with end-
over-end rotation. The bead slurries were then washed four times
with PBS-P, followed by elution of the bound GST proteins with
20 mM GSH/50 mM Tris-CL for 1 hr at 4uC with end-over-end
rotation. Eluted proteins were collected by centrifugation of the
bead slurry, and aspiration of the protein-containing supernatant.
A total of two elutions were carried out in this manner. The two
elutions for each GST-E6 protein were then combined, and
dialyzed using Zeba Desalt Spin Columns (Pierce, Rockford, IL)
and protein buffer (5 mM Tris, 100 mM KCl, 0.5 mM EDTA,
1 mM DTT, 5% glycerol, 0.1%NP40, and protease inhibitor
tablets).
For GST pulldown assays, equal amounts of GST-tagged
proteins were incubated with pre-cleared whole cell HFK lysates
in dialysis buffer (5 mM Tris-HCL pH 7.4, 100 mM KCL,
0.5 mM EDTA, 1 mM DTT, 5% glycerol, 0.1% NP-40, and
protease inhibitor tablets) and gently agitated for one hour at 4uC.
Glutathione sepharose 4B beads were added to each pulldown,
incubated at 4uC for two hours, washed in binding buffer, and
recovered by boiling in 2X sample buffer. The samples were
separated on SDS-polyacrylamide gels, and analyzed by immu-
noblot or for mass spectrometry at our proteomics facility
(FHCRC).
Co-Immunoprecipitation
HA-tagged E6 expressing HFKs were harvested in NP-40 lysis
buffer (1x PBS, 0.5% NP-40, 10% glycerol, 10 mM zinc chloride,
2 mM dithiothreitol, 80 mM b-glycerophosphate, 50 mM sodium
fluoride, 1 mM sodium orthovanadate, and a COMPLETE
protease inhibitor tablet [Roche, Alameda, CA]). Cells were lysed
by sonication for 1 min at 50% duty. Cell debris was pelleted at
14,000 rpm for 15 min and lysates were precleared by rotating at
4uC with 50 mL of protein G agarose (Roche, Alameda, CA). After
centrifugation to remove the beads, lysates were incubated with
the appropriate antibody for 1–2 h at 4uC and purified by adding
protein G agarose and rotating for another hour at 4uC.
Immunocomplexes were washed three times with lysis buffer
and eluted by heating for 10 min at 70uC in 2x sample buffer.
Elutions were electrophoresed on NuPAGE 4%–12% Tris-Bis
gradient gels (Invitrogen, Carlsbad, CA) to resolve HA-tagged E6
proteins and immunoblotted for p300 or HA as described.
RT-PCR
RNA was isolated with Trizol reagent (Invitrogen, Carlsbad,
CA) as previously described [29]. 1 mg of total RNA was reverse
transcribed to generate cDNA, using the iScript cDNA synthesis
kit (BioRad, Hercules, CA). As a negative control, parallel samples
were run without reverse transcriptase. Non-quantitative PCR
amplification was then performed to identify 100 bp amplicons
with E6 and 36B4 primers as previously described [29]. For real-time
RT-PCR, RNA was isolated and reverse transcribed as above, and
quantitative real-time PCR was performed using an ABI 9700
sequence detection system (Applied Biosystems, Foster City, CA).
Amplification was carried out using TaqMan master mix and
the following pre-designed Taqman primer/probes: GAPDH
(4333764F), p300 (Hs00914223_m1), Krt1 (Hs00196158_m1),
Krt10 (Hs00166289) and IVL (Hs00846307_s1) according to the
manufacturer’s instructions (Applied Biosystems, Foster City, CA).
Reactions were performed in triplicate in a 25 ml volume, with the
following cycle parameters: enzyme activation (10 min at 95uC),
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1i na t6 0 uC). Data analysis was performed using the comparative
threshold cycle method (Applied Biosystems, Foster City, CA) to
determine relative expression levels.
Immunoblotting
Whole-cell lysates were prepared by mechanically detaching
cells in cold PBS and resuspending in WE16th lysis buffer (50 mM
Tris-HCL at pH 7.5, 250 mM NaCl, 5 mM EDTA, 1% NP-40,
0.1% sodium dodecyl sulfate, 20% glycerol, 80 mM b-glycero-
phosphate, 50 mM sodium fluoride, 1 mM sodium orthovana-
date, and a COMPLETE protease inhibitor tablet [Roche,
Alameda, CA]). Lysates were then sonicated and clarified by
centrifugation. The DC protein assay (Biorad, Hercules, CA) was
used to determine protein concentrations. For immunoblotting of
differentiation markers K1, K10 and involucrin, cells were lysed
directly in 2X sample buffer (100 mM Tris pH 6.8, 4% SDS, 20%
glycerol, 0.8% bromophenol blue). Equal amounts of protein
lysates (15 to 30 mg) were electrophoresed on SDS-polyacrylamide
gels and transferred to Immobilon-P membranes (Millipore,
Billerica, MA). For quantification of western blot data, the
membranes were scanned and bands were analyzed by densitom-
etry using ImageJ (NIH).
Competition assays
In-vitro competition assays were performed using a protocol
modified from [80]. Briefly, 250 ng of recombinant FLAG-p300
was pre-incubated with equimolar amounts of either His-AKT1 or
GST-E6 in modified HAT buffer (50 mM Tris-HCL, pH 8.0,
10% glycerol, 1 mM DTT, 0.1 mM EDTA, 100 mM KCL, 0.1%
NP40, Complete protease inhibitor tablet (Roche)) for 1 hr at 4uC
with rotation. Increasing concentrations (molar excess 5x–20x), of
GST-E6 or His-AKT1 (5x–10x), were added, and further
incubated for 1 hr before the addition of 50 ml of anti-FLAG
M2 affinity gel. Samples were then rotated at 4uC for 2 hr, washed
4 times with modified HAT buffer, and eluted with 2x SDS-PAGE
sample buffer for 5 min at 100uC.
Chromatin IP
Chromatin immunoprecipitations were performed using the
Enzymatic Chromatin IP (Magnetic bead) kit (Cell Signaling
Technology), as per the manufacturer’s instructions, with minor
modifications. Briefly, chromatin from fixed cells was digested to a
size range of 150–1000 bases with micrococcal nuclease, followed
by brief sonication to disrupt the nuclear membrane. Solubilized
chromatin was immunoprecipitated with antibodies to p300(N-15)
or IgG control. Antibody-chromatin complexes were pulled-down
using ChIP-grade protein-G magnetic beads, washed and then
eluted. After cross-link reversal and proteinase K treatment,
immunoprecipitated DNA was extracted with phenol-chloroform,
and ethanol precipitated. Real-time RT-PCR was performed
using SYBR green and primers to the distal AP1 site of the
involucrin promoter with the following sequences: 59-GCTCA-
CACATACCATCTTCTCCTTA-39 (forward) and 59-CACCG-
GTCTTATGGGTTAGCA-39 (reverse). Standard curves were
calculated using serial dilutions of the input sample, and used to
calculate the relative amount of product amplified in each
reaction. Results were calculated based on the relative enrichment
of protein over that seen with the RPL30 control.
Statistics
All statistics calculations were performed using a two-tailed
student’s T-test.
Supporting Information
Figure S1 Levels of AKT and pAKT during differentia-
tion. Representative immunoblot showing levels pAKT, and total
AKT protein in LXSN, 8E6 and 38E6-expressing HFKs during
48hr calcium-induced differentiation. Actin levels are shown as a
loading control.
(TIFF)
Figure S2 Cell morphology during calcium differentia-
tion. Representative micrographs of each cell line during a typical
calcium differentiation timecourse. All images were acquired
immediately prior to sample harvesting at the respective timepoint.
(TIFF)
Table S1 Proteins identified as potential E6-interactors
via mass-spec. Values represent unique peptides mapping to
each protein in each run. Proteins were identified as a potential
candidate based on the following filters: DiffScore.=0.1, Ion
percent.=0.3, and at least 2 unique peptides for a given protein.
(XLSX)
Table S2 HPV E6 alignment. Sequence comparisons of HPV
E6 proteins at the previously identified 8E6-p300 binding site.
(DOCX)
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